6,678 trials
Obesity, Morbid · Spinal Anesthesia · Cesarean Delivery
Primary: Number of Participants With Successful Blocks for Induction (Success Induction) — 1; 3; 27; 11 Participants
Chondromalacia · Osteoarthritis · Traumatic Arthritis
Primary: 100 mm Visual Analogue Score (VAS) — 32.11; 41.14 score on a scale
Hiv
Primary: M:P Ratio — 0.26; 0.0085 ratio
Tinnitus, Subjective · Tinnitus
Primary: Tinnitus Functional Index (TFI) — -12.1; -12.4; -6.0 scores on a scale
Insomnia · Metabolic Health · Menopause
Primary: Change From Baseline in Insomnia Severity Index (ISI) Score at 4 Weeks — 14.6; 14.5; -5.8; -2.7 units on a scale — p=0.04
Hyperlipidemias
Primary: Percent Change in LDL Cholesterol From Baseline to 12 Months — -46.6 Percent (%)
Smoking · Smoking Cessation
Primary: Enrollment in Study — 36.5 percentage of people invited who enrolle
Diabetes Mellitus · Diabetic Kidney Disease · Hypertension
Primary: To Investigate the Modifying Effect of Sodium Intake on Ertugliflozin on Blood Pressure — 125; 121; 138; 133 mmHg — p=0.0174
HIV · AIDS · Smoking Cessation
Primary: 7-day Point-prevalence Abstinence — 16; 12; 110; 114 Participants
Hypercholesterolemia
Primary: Number of Participants Achieving Individual LDL-C Target (<55 mg/dL or <70 mg/dL) — 752; 266 Participants — p=<0.0001
Pain, Acute · Dissociation
Primary: Side Effect Rating Scale for Dissociative Anesthetics (SERSDA) Composite Score — 1.88; 0.42; 1.17; 3.67 Scores on a Scale — p=<0.001
Attention Deficit Hyperactivity Disorder
Primary: Part A: Change From Baseline in the Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction Time (RTI) Task at Week 18 — -7.1; -9.2; -5.1; 5.3 msec
STI
Primary: doxyPEP DOT Adherence — 1417 Doses
Ophthalmological Agent Toxicity
Primary: The Proportion of Participants Who Decreased ≥ 6 Points or the Equivalent of 20% or More in the Visual Analog Test Score Compared to Their Baseline — 74; 72 Participants
Yellow Fever Vaccination Reaction
Primary: Adverse Events — 26; 27; 28 Participants